U.S. FDA declines to approve Pfizer and OPKO’s growth hormone treatment
By Syndicated ContentJan 21, 2022 | 4:47 PM
(Reuters) – Pfizer Inc and OPKO Health Inc said on Friday the U.S. health regulator declined to approve their application for the experimental growth hormone treatment somatrogon.